FDA Approves Ninlaro for Multiple Myeloma

Share this content:
FDA Approves Ninlaro for Multiple Myeloma
FDA Approves Ninlaro for Multiple Myeloma

FRIDAY, Nov. 20, 2015 (HealthDay News) -- Ninlaro (ixazomib), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat patients with multiple myeloma who have had at least one prior treatment with a different therapy.

Ninlaro, a proteasome inhibitor, is designed to block enzymes that spur the growth and survival of multiple myeloma cells, the FDA said Friday in a news release. Ninlaro is approved in combination with another multiple myeloma drug, Revlimid (lenalidomide), and the corticosteroid drug dexamethasone.

The drug combination was evaluated in clinical studies involving 722 patients. Those who took Ninlaro in tandem with the other two drugs lived for more than 20 months without their disease progressing, compared with about 14 months among those who took a placebo and the other two drugs, the FDA said. Side effects of Ninlaro included diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea/vomiting, and back pain.

"Today's approval is the third drug for multiple myeloma approved this year and provides patients with a new oral treatment that slows disease progression when other therapy has failed," Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Ninlaro is produced by the Japanese drug maker Takeda Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »